Extracellular matrix sheet devices with improved mechanical properties and method of making

Abstract
Described are devices and associated methods of producing extracellular matrix (ECM) sheet devices with strengthened mechanical properties due to the selective retention of muscle tissue layers during processing.
Description
BACKGROUND

Submucosal tissues of warm-blooded vertebrates are useful in tissue grafting materials and have an extensive history of use in surgical applications. In particular, submucosal tissue graft compositions derived from extracellular matrices (ECM), such as urinary bladders, have been described in U.S. Pat. Nos. 5,554,389 and 6,576,265, both incorporated herein by reference. ECM sheet devices are fully-resorbable devices and mitigate the inflammatory response. Importantly, the lack of cross-linking in ECM sheet scaffolds, in contrast to synthetic scaffolds, encourages the repair and remodeling response of damaged tissues post-implantation.


Although ECM devices offer a number of advantages in wound care, physicians are accustomed to working with stronger, permanent devices, such as nylon meshes and polytetrafluoroethylene (PTFE), in surgical applications where suture-retention strength is critical, and are hesitant to use biodegradable ECM devices due to their weaker mechanical properties.


The development of ECM sheet layering has been sufficient to increase the mechanical strength of ECM devices. However, multiple layers in ECM devices decreases the conformability of the ECM device to the underlying tissue at the surgical site. Therefore, a need persists for enhanced, resorbable, ECM sheet devices with strengthened mechanical properties.


SUMMARY

The present disclosure describes the selective retention of muscle tissue during ECM processing, either uniformly or regionally across the entire ECM device to increase mechanical strength and decrease failure rates during surgical and wound healing applications. ECM sheet devices allow for better surgical outcomes than permanent scaffolds, due to their mimicry of mammalian tissue during the wound repair response. Stronger ECM devices also permit ECM to be used in additional surgical applications, such as suture retention strength and to correct bridging defects, which require higher mechanical strength.


To produce extant ECM devices, mammalian tissues are skinned, removing the epithelial layer, and delaminated removing the majority of the muscle tissue.


In contrast, in some embodiments of the present disclosure, the mammalian tissue is not delaminated and the resulting ECM retains residual muscle tissue, enabling ECM devices to retain mechanical strength.


In some embodiments, to retain residual muscle tissue during urinary bladder matrix (UBM) production, harvested porcine bladders go through thawing and preparation, and are subsequently skinned, but do not undergo muscle delamination. In fact, production of UBM from bladders in which the muscle layers were not delaminated was shown to be more time and material efficient and generated less waste than production of UBM in which the muscle tissue was delaminated. Retention of muscle tissue in UBM is also advantageous in that it does not require the use of new reagents, chemical, or additives.


To produce ECM sheets, tissues may also undergo differential scraping in specific regions of the sheet. ECM that are differentially scraped can be layered onto muscle-delaminated ECM sheets, other differentially scraped ECM, or ECM retaining residual muscle tissue. Subsequent processing such as disinfection, decellularization, and lamination occur after the sheet device is configured.


ECM sheets retaining muscle tissue may also be cut into desired reinforcement shapes, such as a frame or strips to reinforce the ECM device as needed for a tissue healing application. These ECM shapes may be layered onto other ECM sheets during the lamination process in order to create the final ECM sheet devices.


In examples, extracellular matrix (ECM) sheet compositions of the present disclosure include at least a decellularized basement membrane, lamina propria, and muscle tissue, wherein an ECM sheet is differentially scraped of the muscle tissue. In some examples, the ECM sheet is layered or stacked with at least one additional ECM sheet.


In some examples, the at least one additional ECM sheet is selected from the group of muscle delaminated ECM sheets, additional differentially scraped ECM sheets, and ECM sheets wherein the residual muscle tissue is fully retained.


In further examples, the ECM sheet is cut into reinforcement shapes, optionally wherein the shapes are frames and/or strips, optionally wherein the frames and/or strips are differentially scraped of muscle tissue in a width of at least 0.1%, 1.0%, 5%, 10%, or 50% of the ECM sheet long-axis diameter, optionally wherein the ECM sheets are scraped of muscle tissue in a pattern selected from the group comprising a straight line, a diagonal line, cross-hatching pattern, and/or circular patterns, optionally wherein the scraping pattern contributes increased mechanical strength to the ECM.


In some examples, the ECM sheets are stacked or staggered in configurations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 16, 17, 18, 19 or 20 layers.


In further examples, the one or more ECM sheets is derived from one or more of the following mammalian tissues: urinary bladder matrix (UBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach, and dermis.


In some examples, the ECM sheet composition comprises at least two muscle delaminated ECM sheets on the top and bottom of the sheet stack, and the composition further comprises at least one differentially scraped ECM sheet or strip.


Examples of a method of making an extracellular matrix (ECM) sheet composition of the present disclosure include removing the surface epithelium of a mammalian tissue to form a de-cellularized tissue having an epithelial basement membrane, lamina propria, and muscle tissue, and scraping the muscle tissue into a pattern.


In further examples, the method of making the ECM sheet composition of the present disclosure provides increased mechanical strength relative to ECM sheet compositions containing no muscle tissue. In some examples, the method of making the ECM sheet composition includes stacking or staggering ECM sheets in configurations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 layers. In some examples, the method of making further includes vacuum drying, lyophilization, vacuum pressing and/or air drying. In some examples, the method of making the ECM sheet compositions employs mammalian urinary bladder matrix (IJBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and/or dermis.


Examples of a method of repairing defects of mammalian tissue of the present disclosure include applying one or more ECM sheet compositions differentially scraped of muscle tissue to a mammalian subject, optionally as a treatment for wound healing, and/or in surgical applications. In example, two or more ECM sheets that are layered and laminated may be scraped of muscle tissue in the same scraping pattern and/or extent or in different scraping patterns and/or extents.





BRIEF DESCRIPTION OF THE DRAWINGS

Reference to the detailed description, in conjunction with the following figures, will make the disclosure more fully understood, wherein:



FIG. 1 illustrates a representative configuration of ECM sheets, e.g. Urinary Bladder Matrix (UBM) sheets in a 3-layer stacking configuration.



FIG. 2 is a flow chart of the manufacturing process of ECM retaining residual muscle tissue.



FIG. 3 illustrates representative embodiments A-F of differential scraping patterns of ECM retaining residual muscle tissue.



FIG. 4 is a graph of the relative DNA content of delaminated UBM (“picked and scraped”) devices and UBM devices retaining residual muscle tissue (“skinned”), in 6-layer configurations.



FIGS. 5A-5C compare the mechanical properties of delaminated UBM devices (“picked and scraped”) and UBM devices retaining residual muscle tissue (“skinned”). FIG. 5A is a graph demonstrating the relative tensile strength of delaminated UBM sheet devices versus muscle-retaining UBM sheet devices in 3 and 6 layer configurations. FIG. 5B is a graph demonstrating the relative suture retention strength of delaminated UBM sheet devices versus muscle-retaining UBM sheet devices in 3 and 6 layer configurations. FIG. 5C is a graph demonstrating the relative tissue thickness of delaminated UBM sheet devices versus muscle-retaining UBM sheet devices in 3 and 6 layer configurations.





DETAILED DESCRIPTION

In the description that follows, like components have the same reference numerals, regardless of whether they present in different examples. To illustrate examples in a clear and concise manner, the drawings may not necessarily illustrate scale and may show certain features in somewhat schematic form. Features described and/or illustrated with respect to one example may exist in the same way or in a similar way in one or more other examples and/or in combination with or instead of the features of the other examples.


As used in the specification and claim for the purposes of describing and defining the invention, the terms “about” and “substantially” represent the inherent degree of uncertainty attributed to any quantitative comparison, value, measurement, or other representation. The terms “about” and “substantially” also represent the degree by which a quantitative representation may vary from a stated reference without resulting in a change in the basic function of the subject matter at issue. “Comprise”, “include”, “have,” and variations of each word include the listed parts and can include additional parts not listed. “And/or” includes one or more of the listed parts and combinations of the listed parts. The terms “upper”, “lower”, “left”, “right” and the like serve to clearly describe the disclosure but do not limit the structure, positioning and/or operation of the disclosure in any manner.


In the instant disclosure, “skinned” tissue refers to tissue wherein the superficial epithelial layer is removed. In some embodiments, the urothelial layer is removed.


In the instant disclosure, the “extracellular matrix” or “ECM” refers to mammalian tissue which has been skinned, removing the superficial epithelial layer, and which comprises at least the basement membrane and lamina propria. In some embodiments the ECM comprises residual muscle tissue including but not limited to the submucosa, the muscularis externa, and/or the tunica serosa, optionally wherein the residual muscle tissue is differentially scraped. In some embodiments the ECM is decellularized. In some embodiments, the ECM is derived from urinary bladder. In other embodiments, the ECM is derived from small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and/or dermis.


In the instant disclosure, “delaminated” refers to full removal of muscle tissue layers including for example, the submucosa, the muscularis externa, and/or the tunica serosa.


In the instant disclosure, “decellularized” refers to removal of cells from a tissue, by any method known in the art, such as methods comprising disinfectants or acidic solutions to produce a decellularized extracellular matrix (ECM) scaffold. In some preferred embodiments, the decellularized ECM encourages the repair and remodeling of damaged tissues post-implantation.


In the instant disclosure, “basement membrane” refers to a thin, pliable sheet-like matrix, that provides cell and tissue support. The basement membrane is between epithelial tissues and the underlying connective tissue.


In the instant disclosure, “lamina propria” refers to a loose connective tissue supporting the mucosal epithelium. Compared to other loose connective tissue, lamina propria in vivo is relatively cellular.


In the instant disclosure, “muscle tissue,” “muscle layers,” or “muscle” refers to the smooth muscle layer in the walls of organs including but not limited to the bladder, bronchi, intestines, and blood vessels. In some embodiments the muscle tissue may include the submucosa, the muscularis externa, and/or the tunica serosa.


In the instant disclosure, “residual muscle tissue” refers to the muscle tissue remaining on mammalian-derived ECM after skinning. The residual muscle tissue may be fully (delaminated) or differentially scraped, or fully retained. In some embodiments, the residual muscle tissue provides increased mechanical strength to the ECM relative to ECM without muscle tissue. In some embodiments, the ECM comprising residual muscle tissue is derived from a urinary bladder, i.e., urinary bladder matrix (UBM). In some embodiments, the ECM is derived from small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and/or dermis.


In the instant disclosure, “reinforcement shape” refers to cutting the ECM, optionally containing residual muscle tissue into any shape that may be then layered onto additional ECM sheets to produce an ECM sheet device. Examples include frames, strips, squares or other desired shapes. ECM in such shapes may be fully or partially scraped of residual muscle tissue.


In the instant disclosure, a “urinary bladder matrix” or “UBM” refers to a urinary bladder that is opened, stretched, and skinned wherein the superficial urothelial layer and the majority of the muscle tissue is removed, thereby leaving a residual layer of muscle tissue. The residual layer of muscle tissue is scraped into differential patterns.


In some embodiments, an “extracellular matrix sheet device,” “ECM device” or “ECM sheet device” is a single ECM sheet. In some embodiments, multiple ECM sheets are stacked and/or staggered in configurations of at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19 or at least 20 layers. Multiple layers of ECM sheets may include combinations of layers that partially or fully retain muscle tissue or which contain no residual muscle tissue. For example, UBM sheet compositions of the present disclosure may comprise 3, 4, 5, 6, 7, or 8 layers of stacked or staggered skinned UBM sheets, or alternating skinned UBM sheets and laminated UBM sheets, or any other layering sequence.


In the instant disclosure, ECM sheet devices may be used to repair defects of mammalian tissue including wound healing and surgical applications. In some embodiments, ECM sheets are used to treat pressure ulcers, venous ulcers, diabetic ulcers, and/or chronic vascular ulcers. In some embodiments, ECM sheets may be used to treat tunneled or undermined wounds. In some embodiments, ECM sheets may be used to treat surgical wounds including but not limited to wounds resulting from donor sites or grafts, post-Mohs surgery, post-laser surgery, podiatric, and/or wound dehiscence. In some embodiments, ECM sheets may be used to treat trauma wounds including but not limited to abrasions, lacerations, second-degree burns, and skin tears, and draining wounds. In some embodiments, ECM sheets may be used to reinforce soft tissue during or after gastroenterological and plastic and reconstructive surgery, including but not limited to, open or laparoscopic procedures, hernia, e.g. hiatal and/or diaphragmatic, body wall repair, colon and rectal prolapse repair, tissue repair, urological repair, esophageal repair, and breast reconstruction. In some embodiments, ECM sheets may be used to minimize tissue attachment to a therapeutic device, e.g. in the case of direct contact with viscera. In some embodiments, ECM sheets may be used to treat to facilitate tissue healing in a mammal during or after surgery wherein mechanical strength is required, e.g. to repair or prevent bridging tissue defects.


In the instant disclosure, “suture retention strength” refers to the resistance of an ECM sheet against the pull-out of a suture. Resistance may be measured by pulling the suture with a constant deformation rate until pull-out of the suture from the scaffold occurs. In some embodiments, the suture strength is measured on INSTRON® tensile testing equipment.


In the instant disclosure, “stacked” and “staggered” refers to any configuration of sheets wherein the UBM sheets may overlap one another completely or partially.


In the instant disclosure, “differentially scraped” refers to scraping residual muscle tissue of an ECM sheet after skinning such that not all of the muscle tissue is removed. In some embodiments, the scraping forms a pattern. In some embodiments, the pattern is one of those embodiments A-F illustrated in FIG. 3. Exemplary patterning may include scraping any width and number of straight lines, diagonal lines, cross-hatching, circular patterns, or any variations thereof. In some embodiments, the pattern contributes increased mechanical strength uniformly and/or regionally to the UBM. In some embodiments, the width of the line scraping may be least 0.1%, at least 1.0%, at least 5%, at least 10%, or at least 50% of the sheet long-axis diameter. Some embodiments include a range of percent width of the line scraping that is a range between any two of the aforementioned percentages. In further embodiments, the percent width of the line scraping is any and all values contained within the ranges between any two of the aforementioned percentages.


In some embodiments the percent residual muscle tissue remaining on the ECM sheet after scraping is at least at least 0.01%, at least 0.1%, at least 0.5%, at least I %, at least 5%, at least 10%, at least 25%, at least 50%, at least 75%, at least 90%, or at least 99% of the residual muscle tissue present before scraping. In addition, some embodiments include a range of percent residual muscle tissue remaining on the ECM sheet that is a range between any two of the aforementioned percentages. In further embodiments, the percent residual muscle tissue remaining on the ECM sheet is any and all values contained within the ranges between any two of the aforementioned percentages.


In the instant disclosure, “dried” or “drying” of an ECM sheet refers to any method known in the art to dry ECM sheets including but not limited to vacuum drying, lyophilization, and/or air drying. In some embodiments, drying methods serve to compress the ECM sheets.


In the instant disclosure, “disinfected and rinsed” refers to ECM sheet device production wherein the ECM sheet devices are disinfected through any method known in the art, e.g. with disinfectants or acidic solutions, to rid the device of any pathogens, and subsequent rinsing of the disinfectant.


In the instant disclosure, “lamination” refers to lamination of the final ECM sheet device configuration. The term “laminate” describes both the process and the end result of two or more independent pieces of tissue bonding together. Thus, lamination produces a directed area of connection between the tissues that would not occur unless intentionally created.



FIG. 1 shows an example of a 3-layer sheet ECM device, e.g. a UBM device, comprising one “skinned” sheet, and two additional UBM sheets. Each ECM sheet may fully retain the residual muscle tissue after skinning, or be fully or partially delaminated. Stacking sheets may increase the height of the device, while in other embodiments, staggering sheets comprises partially overlapping sheets to increase the width of the device.


In FIG. 2, the manufacturing method is shown for producing ECM sheets including basement membrane and lamina propria layers. Step 2 includes skinning the ECM, and Steps 2 and 4 include physical delamination and scraping methods to remove muscle tissue. ECM of the instant disclosure may selectively retain the muscle tissue during the delamination and scraping steps.


In FIG. 3, planar views of ECM embodiments with differential muscle tissue scraping patterns are shown, wherein the darker regions indicate zero or less scraping and the lighter regions indicate more scraping. In many embodiments, patterning may include scraping a preferred width or number of straight lines (embodiments A-C), circular, ellipse or oval patterns (embodiment D), diagonal lines (embodiment E), cross-hatching (embodiment F), or any variations thereof. The preferred pattern may depend on the desired application of the ECM device, and the spatial mechanical properties required for the application. In some embodiments, an ECM device comprising a sheet with a pattern shown in embodiment A, like a frame, may be applied in surgical applications to minimize suture pull-through.


Mechanical and DNA testing of UBM sheet configurations comprising fully delaminated sheets versus sheet configurations comprising residual muscle tissue was performed. It was found that UBM retaining residual muscle tissue did not have significantly increased DNA content compared to fully delaminated UBM, as shown by picogreen DNA assays in FIG. 4. Notably, these results indicate that decellularized UBM sheets containing residual muscle tissue are not expected to induce a pro-inflammatory response upon implantation or grafting in a mammalian patient.


Further, although the tensile strength (FIG. 5A) did not vary linearly between the UBM devices with residual muscle tissue and those devices with fully delaminated UBM sheets, the relative suture retention strength was about 3.5-2× greater for UBM sheet devices with residual muscle tissue than for fully delaminated UBM (FIG. 5B). The thickness of the UBM sheet devices is increased with residual muscle tissue over those of the delaminated extant products (FIG. 5C).


Current UBM surgical products referred to as GENTRIX® Surgical Matrix, comprising delaminated UBM sheets are available in various configurations, including 3, 6, or 6 layers stacked and 8 layers staggered, vacuum pressed to bond the layers together. Vacuum pressing comprises compressing hydrated, remoldable material while subjecting the material to a vacuum. Vacuum pressing can laminate multiple layers of ECM material together by crushing the matrix structure of the ECM. Lyophilization may also be used to produce the final product with multiple layers. The UBM sheet compositions of the instant disclosure, wherein residual muscle tissue is retained on at least one sheet, alone and in various combinations (e.g. multiple layered, stacked and/or staggered in varying degrees and patterns) can address any suture pull through problems associated with the current products, and any other need for enhanced, resorbable, ECM sheet devices with strengthened mechanical properties.


One skilled in the art will realize the disclosure may embody other specific forms without departing from the spirit or essential characteristics thereof. The foregoing examples in all respects illustrate rather than limit the disclosure described herein. The appended claims, rather than the foregoing description, thus indicate the scope of the disclosure, and embrace all changes that come within the meaning and range of equivalency of the claims.

Claims
  • 1. An extracellular matrix (ECM) sheet composition, comprising: decellularized basement membrane, lamina propria, and muscle tissue, wherein an ECM sheet is differentially scraped of the muscle tissue.
  • 2. The composition of claim 1, wherein the ECM sheet is layered or stacked with at least one additional ECM sheet.
  • 3. The composition of claim 2, wherein the at least one additional ECM sheet is selected from the group consisting of muscle delaminated ECM sheets, differentially scraped ECM sheets, and ECM sheets wherein the residual muscle tissue is fully retained.
  • 4. The composition of claim 1, wherein the ECM sheet is cut into reinforcement shapes selected from the group consisting of frames, strips and squares.
  • 5. The composition of claim 4, wherein the frames or strips are differentially scraped of muscle tissue in a width of at least 0.1%, 1.0%, 5%, 10%, or 50% of the ECM sheet long-axis diameter.
  • 6. The composition of claim 1, wherein the ECM sheet is scraped of muscle tissue in a pattern selected from the group consisting of a straight line, a diagonal line, cross-hatching pattern, and/or circular patterns.
  • 7. The composition of claim 1, wherein the ECM sheet is scraped in a scraping pattern that contributes increased mechanical strength to the ECM.
  • 8. The composition of claim 2, wherein the ECM sheets are stacked or staggered in configurations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 layers.
  • 9. The composition of claim 1, wherein the ECM sheet is derived from a mammalian tissue selected from the group consisting of: urinary bladder matrix (UBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and dermis.
  • 10. The composition of claim 2, wherein the at least one additional ECM sheet is derived from a mammalian tissue selected from the group consisting of: urinary bladder matrix (UBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and dermis.
  • 11. The composition of claim 2, comprising at least two muscle delaminated ECM sheets on the top and bottom of the sheet stack.
  • 12. The composition of claim 11, further comprising at least one differentially scraped ECM sheet or strip.
  • 13. A method for manufacture of an extracellular matrix (ECM) sheet composition, comprising: removing the surface epithelium of a mammalian tissue to form a decellularized tissue having an epithelial basement membrane, lamina propria, and muscle tissue, and scraping the muscle tissue into a pattern.
  • 14. The method of claim 13, wherein the ECM sheet exhibits increased mechanical strength relative to ECM sheets containing no muscle tissue.
  • 15. The method of claim 13, further comprising stacking or staggering ECM sheets in configurations of at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 layers.
  • 16. The method of claim 13, further comprising vacuum drying, lyophilization, vacuum pressing, and/or air drying the ECM sheet.
  • 17. The method of claim 13, wherein the ECM sheet is derived from one or more mammalian tissues selected from the group consisting of: urinary bladder matrix (UBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and dermis.
  • 18. The method of claim 15, wherein the ECM sheets are individually derived from mammalian tissue selected from the group consisting of: urinary bladder matrix (UBM), small intestine submucosa (SIS), spleen, liver, lung, heart, pancreas, ovary, forestomach and dermis.
  • 19. A method of repairing defects of mammalian tissue comprising applying one or more ECM sheets differentially scraped of muscle tissue and comprising decellularized basement membrane, lamina propria, and muscle tissue to a mammalian subject, as a treatment for wound healing, and/or in surgical applications.
  • 20. The method of claim 19, wherein two or more ECM sheets which are scraped of muscle tissue in the same scraping pattern or in different scraping patterns are layered and laminated.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority to and benefit under 35 U.S.C. 119(e) to U.S. Provisional Application No. 63/131,600, filed Dec. 29, 2020, the entire contents of which are incorporated by reference herein.

US Referenced Citations (209)
Number Name Date Kind
4902508 Badylak et al. Feb 1990 A
4956178 Badylak et al. Sep 1990 A
4978668 Babbs et al. Dec 1990 A
5007927 Badylak et al. Apr 1991 A
5275826 Badylak et al. Jan 1994 A
5281422 Badylak et al. Jan 1994 A
5354274 Demeter et al. Oct 1994 A
5372821 Badylak et al. Dec 1994 A
5445833 Badylak et al. Aug 1995 A
5516533 Badylak et al. May 1996 A
5554389 Badylak et al. Sep 1996 A
5573784 Badylak et al. Nov 1996 A
5641518 Badylak et al. Jun 1997 A
5645860 Knapp et al. Jul 1997 A
5695998 Badylak et al. Dec 1997 A
5711969 Patel et al. Jan 1998 A
5753267 Badylak et al. May 1998 A
5755791 Whitson et al. May 1998 A
5762966 Knapp et al. Jun 1998 A
5866414 Badylak et al. Feb 1999 A
5885619 Patel et al. Mar 1999 A
5955110 Patel et al. Sep 1999 A
5968096 Whitson et al. Oct 1999 A
5997575 Whitson et al. Dec 1999 A
6096347 Geddes et al. Aug 2000 A
6099567 Badylak et al. Aug 2000 A
6126686 Badylak et al. Oct 2000 A
6187039 Hiles et al. Feb 2001 B1
6206931 Cook et al. Mar 2001 B1
6241981 Cobb et al. Jun 2001 B1
6331319 Badylak et al. Dec 2001 B1
6358284 Fearnot et al. Mar 2002 B1
6375989 Badylak et al. Apr 2002 B1
6379710 Badylak et al. Apr 2002 B1
6475232 Babbs et al. Nov 2002 B1
6485723 Badylak et al. Nov 2002 B1
6576265 Spievack Jun 2003 B1
6579538 Spievack Jun 2003 B1
6653291 Badylak et al. Nov 2003 B1
6696074 Dai et al. Feb 2004 B2
6696270 Badylak et al. Feb 2004 B2
6783776 Spievack Aug 2004 B2
6793939 Badylak et al. Sep 2004 B2
6849273 Spievack Feb 2005 B2
6852339 Spievack Feb 2005 B2
6861074 Spievack Mar 2005 B2
6869619 Spievack Mar 2005 B2
6887495 Spievack May 2005 B2
6890562 Spievack May 2005 B2
6890563 Spievack May 2005 B2
6890564 Spievack May 2005 B2
6893666 Spievack May 2005 B2
6969523 Mattern et al. Nov 2005 B1
7087089 Patel et al. Aug 2006 B2
7354702 Dai et al. Apr 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7485138 Fearnot et al. Feb 2009 B2
7597710 Obermiller Oct 2009 B2
7652077 Cook et al. Jan 2010 B2
7745217 Patel et al. Jun 2010 B2
7771717 Badylak et al. Aug 2010 B2
7776596 Badylak et al. Aug 2010 B2
7795022 Badylak et al. Sep 2010 B2
7795027 Hiles Sep 2010 B2
7815923 Johnson et al. Oct 2010 B2
7897167 Armstrong et al. Mar 2011 B2
7914567 Pavcnik et al. Mar 2011 B2
7959554 McAlexander et al. Jun 2011 B2
7993679 Ingram et al. Aug 2011 B2
8187619 Johnson May 2012 B2
8192763 Johnson Jun 2012 B2
8211168 Purdy et al. Jul 2012 B2
8298586 Bosley et al. Oct 2012 B2
8357402 Ingram et al. Jan 2013 B2
8409625 Badylak et al. Apr 2013 B2
8444687 Pavcnik et al. May 2013 B2
8454678 Hiles Jun 2013 B2
8455008 Johnson Jun 2013 B2
8535349 Chen et al. Sep 2013 B2
8541032 Bosley et al. Sep 2013 B2
8541372 Shah et al. Sep 2013 B2
8557277 Virkler et al. Oct 2013 B2
8591930 Hiles et al. Nov 2013 B2
8647677 Badylak et al. Feb 2014 B2
8652191 Fearnot et al. Feb 2014 B2
8652500 Bosley et al. Feb 2014 B2
8658196 Janis Feb 2014 B2
8663086 Duncan et al. Mar 2014 B2
8716227 Cook et al. May 2014 B2
8741352 Hodde et al. Jun 2014 B2
8784889 Hodde et al. Jul 2014 B2
8790414 O'Brien et al. Jul 2014 B2
8802436 Kentner et al. Aug 2014 B1
8808352 Eells et al. Aug 2014 B2
8835174 Fette et al. Sep 2014 B2
8840917 Armstrong et al. Sep 2014 B2
8846060 Archibald et al. Sep 2014 B2
8895304 Ette et al. Nov 2014 B2
8915941 Obermiller et al. Dec 2014 B2
8927003 Badylak et al. Jan 2015 B2
8932805 Brahm Jan 2015 B1
8962035 Bosley et al. Feb 2015 B2
8968761 Bosley et al. Mar 2015 B2
8975075 Fette et al. Mar 2015 B2
9011895 Dai et al. Apr 2015 B2
9044455 Shah et al. Jun 2015 B2
9056078 Bosley et al. Jun 2015 B2
9084722 Gilbert et al. Jul 2015 B2
9113851 Agnew Aug 2015 B2
9119831 Kentner et al. Sep 2015 B2
9138445 Hodde Sep 2015 B2
9149262 Obermiller et al. Oct 2015 B2
9186435 Hiles Nov 2015 B2
9226736 Obermiller et al. Jan 2016 B2
9238091 Kentner et al. Jan 2016 B2
9254188 Dempsey Feb 2016 B2
9265860 Spievack Feb 2016 B2
9295757 Patel et al. Mar 2016 B2
9404077 Fette et al. Aug 2016 B2
9433701 Spievack Sep 2016 B2
9456813 Obermiller et al. Oct 2016 B2
9456815 Armstrong et al. Oct 2016 B2
9474514 Agnew et al. Oct 2016 B2
9474829 Kentner et al. Oct 2016 B2
9480771 Fette et al. Nov 2016 B2
9492149 Obermiller et al. Nov 2016 B2
9492267 Hiles Nov 2016 B2
9498327 Brahm Nov 2016 B1
9504769 Hiles et al. Nov 2016 B2
9538996 Patel et al. Jan 2017 B2
9561307 Bosley et al. Feb 2017 B2
9572556 Obermiller et al. Feb 2017 B2
9579183 Bosley et al. Feb 2017 B2
9585983 Brahm Mar 2017 B1
9687215 Obermiller et al. Jun 2017 B2
9764056 Fette et al. Sep 2017 B2
9788821 Johnson et al. Oct 2017 B2
9789138 Brahm et al. Oct 2017 B1
9795638 Brahm Oct 2017 B1
9795639 Brahm Oct 2017 B1
9795713 Kentner et al. Oct 2017 B2
9839721 Mohan et al. Dec 2017 B2
9855301 Brahm Jan 2018 B1
9861517 Pavcnik et al. Jan 2018 B2
9919078 Brahm Mar 2018 B1
9931439 Fearnot et al. Apr 2018 B2
9956315 Patel et al. May 2018 B2
9993506 Brahm Jun 2018 B1
9999707 Gilbert et al. Jun 2018 B2
10010659 Brahm et al. Jul 2018 B1
10016459 Brahm Jul 2018 B1
10071187 Hiles et al. Sep 2018 B2
10092678 Spievack Oct 2018 B2
10245349 Brahm Apr 2019 B2
10265438 Brahm Apr 2019 B1
10342523 Obermiller et al. Jul 2019 B2
10470749 Obermiller et al. Nov 2019 B2
10471182 Hiles et al. Nov 2019 B2
10500309 Shah et al. Dec 2019 B2
10517994 Bosley et al. Dec 2019 B2
10555974 Brahm Feb 2020 B1
10568914 Brahm Feb 2020 B1
10688219 Patel et al. Jun 2020 B2
10786600 Brahm Sep 2020 B1
10806833 Pomrink et al. Oct 2020 B1
10898610 Bosley et al. Jan 2021 B2
10905798 Brahm Feb 2021 B1
10905800 Brahm Feb 2021 B1
11000628 Bosley et al. May 2021 B2
11013829 Bosley et al. May 2021 B2
11026667 Agnew et al. Jun 2021 B2
11064987 Obermiller et al. Jul 2021 B2
11065368 Peck et al. Jul 2021 B2
11077229 Brahm Aug 2021 B1
11077231 Hiles et al. Aug 2021 B2
11167061 Brahm Nov 2021 B1
11173231 Hiles et al. Nov 2021 B2
11185611 Gilbert et al. Nov 2021 B2
11224616 Brahm Jan 2022 B1
11224617 Brahm Jan 2022 B1
20040043006 Badylak et al. Mar 2004 A1
20040078076 Badylak et al. Apr 2004 A1
20040187877 Badylak et al. Sep 2004 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050182484 Patel et al. Aug 2005 A1
20060136047 Obermiller et al. Jun 2006 A1
20060251702 Janis et al. Nov 2006 A1
20070166395 McAlexander Jul 2007 A1
20070179507 Shah Aug 2007 A1
20070184122 Johnson et al. Aug 2007 A1
20080167728 Cook et al. Jul 2008 A1
20090318934 Johnson et al. Dec 2009 A1
20110060362 Patel et al. Mar 2011 A1
20150258142 Dhanaraj Sep 2015 A1
20160089477 Valmikinathan et al. Mar 2016 A1
20160206785 Patel et al. Jul 2016 A1
20170072099 Hiles et al. Mar 2017 A1
20170086808 Patel et al. Mar 2017 A1
20180036451 Fette et al. Feb 2018 A1
20180043057 Kentner et al. Feb 2018 A1
20180228939 Hiles et al. Aug 2018 A1
20180280574 Gilbert et al. Oct 2018 A1
20190046211 Bronikowski et al. Feb 2019 A1
20190336650 Hiles et al. Nov 2019 A1
20200129666 Bosley et al. Apr 2020 A1
20200188559 Hiles et al. Jun 2020 A1
20200316257 Patel et al. Oct 2020 A1
20210077661 Valmikinathan et al. Mar 2021 A1
20210308342 Peck et al. Oct 2021 A1
Non-Patent Literature Citations (1)
Entry
US 7,608,454 B2, 10/2009, Badylak et al. (withdrawn)
Provisional Applications (1)
Number Date Country
63131600 Dec 2020 US